A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 04 Jan 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research